Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-30T20:31:07.084Z Has data issue: false hasContentIssue false
  • English
  • Français

Maintenance doses for clozapine

Published online by Cambridge University Press:  02 January 2018

Bernadette Murphy ,
Colm Long  and
Carol Paton
Bernadette Murphy
Affiliation:
Oxleas NHS Trust, Bexley Hospital, Old Bexley Lane, Bexley, Kent DA5 2BW
Colm Long
Affiliation:
Oxleas NHS Trust, Bexley Hospital, Old Bexley Lane, Bexley, Kent DA5 2BW
Carol Paton*
Affiliation:
Oxleas NHS Trust, Bexley Hospital, Old Bexley Lane, Bexley, Kent DA5 2BW
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The British National Formulary (BNF) entry for clozapine clearly distinguishes the treatment dose (200–450 mg daily, maximum 900 mg) from the maintenance dose (150–300 mg daily). We looked at 44 patients maintained on clozapine locally and found that 36 (82%) received doses above the BNF guidelines. This has considerable cost implications. While it is always good practice to maintain patients on the lowest possible dose of antipsychotic, the BNF guidelines are not based on objective outcome data, and should be treated cautiously.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 22 , Issue 1 , January 1998 , pp. 12 - 14
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists

References

Devinsky, O., Honigfeld, G. & Patin, J. (1991) Clozapinerelated seizures. Neurology, 41, 369–371.Google Scholar
Gerson, S. L. & Meltzer, H. (1992) Mechanisms of clozapine-induced agranulocytosis. Drug Safety, 7 (suppl. 1), 17–25.CrossRefGoogle ScholarPubMed
Kane, J. M. (1992) Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. British Journal of Psychiatry, 160 (suppl. 17), 41–45.Google Scholar
Lieberman, J. A. & Safferman, A. Z. (1992) Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly, 63, 51–70.Google Scholar
Meltzer, H. & Okayli, G. (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry, 152, 183–190.Google ScholarPubMed
Paton, C. & Wolfson, P. M. (1996) Is clozapine TDM therapeutic: a naturalistic study to evaluate the relationship between clozapine serum levels and clinical effect. Journal of Pharmacy Practice, 6, 371–373.Google Scholar
Perry, P. J., Miller, D. D., Arndt, S. V., et al (1991) Clozapine and norclozapine plasma concentrations and clinical response to treatment-refractory schizophrenic patients. American Journal of Psychiatry, 148, 231–235.Google Scholar
Taylor, D. & Duncan, D. (1995) The use of clozapine plasma levels in optimising therapy. Psychiatric Bulletin, 19, 753–755.Google Scholar
Special Hospitals Treatment Resistant Schizophrenia Research Group (1996) Schizophrenia, violence. clozapine and risperidone: a review. British Journal of Psychiatry, 169 (suppl. 31), 21–30.CrossRefGoogle Scholar
Wolfson, P. M. & Paton, C. (1996) Clozapine audit: what do the patients and relatives think? Journal of Mental Health, 5, 267–273.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.